P2RY12 and myocardial infarction: However, some studies have confirmed that compared with clopidogrel, the new P2Y2 inhibitor significantly reduced the incidence of stent thrombosis, all-cause mortality, and myocardial infarction, while the bleeding risk increased.[28] There are some differences in the use of P2Y12 inhibitors in DAPT in the early stage, which could also be an important limitation of this study.